Welcome to our dedicated page for Immunogen news (Ticker: IMGN), a resource for investors and traders seeking the latest updates and insights on Immunogen stock.
Immunogen Inc (IMGN) is a clinical-stage biotechnology leader pioneering targeted cancer therapies through its proprietary antibody-drug conjugate (ADC) technology. This dedicated news hub provides investors and industry professionals with timely updates on IMGN's scientific advancements, regulatory milestones, and strategic partnerships.
Our curated collection offers immediate access to official press releases, clinical trial developments, and collaboration announcements. Users will find updates on oncology research progress, FDA interactions, and technology licensing agreements that shape IMGN's position in the biopharmaceutical landscape.
Key content types include pipeline advancements for solid tumor treatments, partnership expansions with major pharmaceutical companies, and financial disclosures. The platform serves as a reliable resource for understanding how IMGN's ADC platform addresses complex oncology challenges through precision-targeted therapeutics.
Bookmark this page for streamlined tracking of IMGN's scientific and corporate developments. Combine these updates with Stock Titan's analysis tools to monitor the company's progress in transforming cancer treatment paradigms.
ImmunoGen, Inc. has announced the grant of stock options to purchase 1,295,950 shares to 27 new employees, effective June 30, 2022, under its Inducement Equity Incentive Plan. This move aligns with Nasdaq Listing Rule 5635(c)(4) and is designed to attract new talent. The options have an exercise price of $4.50 per share, equal to the company's closing stock price on the grant date, and will vest over four years. ImmunoGen focuses on developing antibody-drug conjugates aimed at improving cancer treatment outcomes.
ImmunoGen Inc. has announced a new multi-year collaboration with Oxford BioTherapeutics to develop novel antibody-drug conjugates (ADCs) targeting cancers with high unmet needs. The partnership will leverage ImmunoGen's proprietary linker-payload technology and OBT's OGAP® discovery platform. OBT will receive an upfront payment and both companies are eligible for milestone payments and tiered royalties. This deal aims to expand ImmunoGen's ADC capabilities and strengthen its oncology pipeline.
ImmunoGen, Inc. (Nasdaq: IMGN) announced the approval of stock options for 365,920 shares to fourteen new employees on May 31, 2022. This grant is part of the Inducement Equity Incentive Plan aimed at attracting new talent. The stock options have an exercise price of $3.66 per share, equivalent to the stock's closing price on the same day. Options will vest over four years, with 25% vesting after one year and 6.25% quarterly thereafter, contingent upon continued employment.
ImmunoGen, Inc. has announced significant data on mirvetuximab soravtansine at the 2022 ASCO Annual Meeting. Updated results from the SORAYA study show an objective response rate (ORR) of 32.4% in patients with platinum-resistant ovarian cancer, with tumor reduction in 71.4% of cases. The median overall survival is reported as 13.8 months. Additionally, an integrated safety summary from 464 patients indicates a favorable safety profile for mirvetuximab, with the most common treatment-related adverse events being manageable low-grade effects. The drug's biologics license application has been filed with the FDA.
ImmunoGen, Inc. (NASDAQ: IMGN), a leader in antibody-drug conjugates (ADCs) for cancer treatment, announced upcoming presentations at investor conferences. The first is at the William Blair 42nd Annual Growth Stock Conference on June 8 at 11:20am CT/ 12:20pm ET. The second will be at the Jefferies Healthcare Conference on June 9 at 9:30am ET. Webcasts will be available on the company’s website, along with replays after the events. ImmunoGen aims to improve cancer treatment outcomes through innovative ADCs.
ImmunoGen, Inc. announces the FDA's acceptance and filing of its Biologics License Application (BLA) for mirvetuximab soravtansine, targeting FRα-high platinum-resistant ovarian cancer. This BLA has received Priority Review, with a decision expected by
ImmunoGen, Inc. (NASDAQ: IMGN) announced that CFO Susan Altschuller will present at the H.C. Wainwright Global Investment Conference on May 24, 2022, at 7:00 am ET. The presentation will be available via webcast on the company's website, with a replay accessible afterward. ImmunoGen focuses on developing innovative antibody-drug conjugates (ADCs) to enhance cancer treatment outcomes, demonstrating a commitment to improving patient experiences with targeted therapies.
ImmunoGen has submitted a Biologics License Application (BLA) for mirvetuximab soravtansine to the FDA under the accelerated approval pathway for ovarian cancer treatment. The submission follows positive results from the pivotal SORAYA trial. The company anticipates a PDUFA date later this year and is ramping up commercialization efforts. Total revenues for Q1 2022 were $38.1 million, a significant increase from $15.7 million in Q1 2021, driven by collaboration fees. Operating expenses rose to $60.9 million, leading to a net loss of $24.1 million.
ImmunoGen, Inc. (NASDAQ: IMGN) announced on April 29, 2022, that its Board of Directors approved the grant of non-qualified stock options for 729,530 shares to 16 new employees under the Inducement Equity Incentive Plan. The exercise price is set at $4.83 per share, matching the closing stock price on that day. These options vest over four years, with 25% vesting after one year and subsequent quarterly vesting. This plan is aimed at attracting talent and facilitating employment with the company.
ImmunoGen Inc. (NASDAQ: IMGN) has announced a conference call on May 6, 2022, at 8:00 a.m. ET, to discuss its Q1 2022 operating results and provide business updates. The call can be accessed by dialing (877) 621-5803 with conference ID 5444669, or through the company’s website. ImmunoGen focuses on developing antibody-drug conjugates aimed at improving cancer treatment outcomes and enhancing patient quality of life. Their mission is encapsulated in the phrase “TARGET A BETTER NOW™”.
FAQ
What is the market cap of Immunogen (IMGN)?
